NWRD09 for Genital Warts
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called NWRD09 for genital warts caused by a persistent HPV16 infection, a common virus affecting the skin and mucous membranes. The goal is to determine if NWRD09 is safe and effective for treating these warts. Participants will be divided into groups, with some receiving the actual treatment and others a placebo (inactive substance). Women who have had an HPV16 infection for at least six months and exhibit specific abnormal cell changes in their cervix might be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop taking my current medications for the trial?
The trial requires that you stop using systemic corticosteroids and immunosuppressants at least 30 days before screening. If you are on disease-modifying antirheumatic drugs (DMARDs) or biologic DMARDs, you cannot use them during the study.
Is there any evidence suggesting that NWRD09 is likely to be safe for humans?
Research has shown that NWRD09 is being tested for safety in treating HPV16 infections. Some studies suggest that people generally tolerate the treatment well. Although exact numbers aren't always available, researchers closely monitor any side effects. They aim to ensure that any serious side effects are rare or manageable.
Since this study is in its early stages, researchers are still learning about the treatment's safety. Early studies often focus on finding the safest doses and identifying possible side effects. So far, no major safety issues have been reported, but more data will help confirm this as the trials continue.12345Why do researchers think this study treatment might be promising?
Most treatments for genital warts, like topical creams or cryotherapy, aim to remove visible warts but don't directly target the virus causing them. NWRD09 is unique because it works differently, targeting the underlying human papillomavirus (HPV) directly, which could potentially reduce the recurrence of warts. Researchers are excited about NWRD09 because it offers a new mechanism of action that might not only treat existing warts but also prevent new ones from forming, which is a significant advancement over current options.
What evidence suggests that NWRD09 might be an effective treatment for genital warts?
Research has shown that immunotherapies hold promise for treating warts, especially when standard treatments fail. Studies have found these therapies to be effective and generally well-tolerated. In this trial, participants will receive either NWRD09 or a placebo. While specific information on NWRD09 remains limited, researchers believe it may help by boosting the body's immune system to fight and clear HPV infections. Early signs suggest this method could be effective for persistent HPV16 infections, which often cause genital warts. Although more research is needed, initial results offer hope for NWRD09 as a potential treatment.678910
Are You a Good Fit for This Trial?
This trial is for women aged 18-60 who have had a confirmed HPV16 infection for at least 6 months and certain abnormal cervical cell results. Participants must not be pregnant, agree to use contraception, and have normal major organ function.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive NWRD09 or placebo to evaluate safety, tolerability, immunogenicity, and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NWRD09
Trial Overview
The study is testing a new drug called NWRD09 compared to a placebo in women with persistent HPV16 infection. It aims to find the safest dose and see how well the drug works against the virus.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Predefined dose groups of NWRD09
Find a Clinic Near You
Who Is Running the Clinical Trial?
Newish Biotech (Wuxi) Co., Ltd.
Lead Sponsor
Citations
Condylomata Acuminata (Genital Warts) - StatPearls - NCBI
Isotretinoin therapy is most effective when combined with other genital wart treatments, including surgical debulking, cryotherapy, interferon-alfa-2a, and ...
Condylomata acuminata: A retrospective analysis on clinical ...
59.8 % of patients were diagnosed with genital warts for the first time, having suffered from CA for less than three months prior to consulting the clinic ( ...
3.
researchgate.net
researchgate.net/publication/365715350_Photodynamic_therapy_in_the_treatment_of_condyloma_acuminata_A_systematic_review_of_clinical_trials(PDF) Photodynamic therapy in the treatment of condyloma ...
A significant value of complete response (CR) ranging from 63-100% in patients with genital warts after receiving several sessions of PDT. A ...
Genital Warts (Condylomata Acuminata)
A 32-year observational study from Italy found that over the period from 1991 through 2022, the frequency of anogenital warts decreased. A study ...
Genital Warts: A Comprehensive Review | JCAD
In fact, approximately 30 percent of all warts will regress within the first four months of infection. Unfortunately, long-term remission rates remain largely ...
Safety and Efficacy Study of NWRD09 in HPV-16 ... - AdisInsight
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA ...
Study Details | NCT06741150 | NWRD09 for HPV-16 ...
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA ...
Study Details | NCT07536282 | Evaluation of NWRD09 for ...
This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female ...
NWRD09 for Genital Warts · Info for Participants
This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with ...
Safety of Human Papillomavirus 9-Valent Vaccine - PMC - NIH
In clinical trials and meta-analysis, the tetravalent HPV vaccine was found to be safe and efficacious [8, 9]. A recent observational study with human ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.